

## References

### I-209

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. S. Department of Health and Human Services, National Institutes of Health, National Center for Advancing Translational Sciences. (2019). Genetic and Rare Diseases (GARD) Information Center.
3. Micromedex® Solutions Compendia. 2020. Emapalumab-lzsg.
4. Emapalumab-lzsg. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020.
5. Gamifant™ (emapalumab-lzsg) injection, for intravenous use [package insert]. Sobi, Inc. Waltham, MA. Revised 11/2018.
6. Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM, et al. A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. *Medicine*. 2018;97(31):1-9.
7. Jordan MB. Emergence of targeted therapy for hemophagocytic American Society of Hematology. 2018;15(2):1-8.
8. Louder DT, Bin Q, de Min C, et al. Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections. *Blood Advances*. 2019; 3(1):47-50.
9. Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. *Blood*. 2019;134(21):1783-1786.
10. Al-Salama ZT. Emapalumab: first global approval. *Drugs*. 2019;79(99): 103-108.